Abstract
Maternal prenatal infections have been linked to children’s neurodevelopment and cognitive outcomes. It remains unclear, however, whether infections occurring during specific vulnerable gestational periods can affect children’s cognitive outcomes. The study aimed to examine maternal infections in each trimester of pregnancy and associations with children’s verbal, performance, and total IQ scores. The ALSPAC birth cohort was used to investigate associations between maternal infections in pregnancy and childhood IQ outcomes. Infection data from mothers and cognition data from children were included with the final study sample size comprising 7,410 mother-child participants. Regression analysis was used to examine links between maternal infections occurring at each trimester of pregnancy and children’s cognitive IQ scores at 18 months, 4 years, and 8 years. Infections in the third trimester were significantly associated with decreased verbal IQ at age 4 (p<.05, adjusted R2 = .004); decreased verbal IQ (p<.01, adjusted R2 = .001), performance IQ (p<.01, adjusted R2 = .0008), and total IQ at age 8 (p<.01, adjusted R2 = .001). Results suggest that later maternal infections could have a latent effect on cognitive development, only emerging when cognitive load increases over time, though magnitude of effect appears to be small. Performance IQ may be more vulnerable to trimester-specific exposure to maternal infection as compared to verbal IQ. Future research could include examining potential mediating mechanisms on childhood cognition, such as possible moderating effects of early childhood environmental factors, and if effects persist in future cognitive outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the following body throughout the course of this project: the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 813546. The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees, with informed consent for the use of data collected via questionnaires and clinic records obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. Ethics approval was obtained from the Bristol and Weston Health Authority: E1808, and the United Bristol Healthcare Trust: E4445 ALSPAC Focus at Eight.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
